−3.9%
since Sep 29
The idea
I'm betting personalized medicine, treatments built around your own tumor or DNA, becomes standard care over the next decade or two, not just a Covid-era blip. Since nobody can pick which specific drug wins its trials, most of the portfolio sits in the sequencing, lab tools, and manufacturing suppliers who get paid regardless of whose therapy succeeds, with smaller slices in the platform makers themselves, big pharma partners for ballast, and diagnostics to round it out.
What it owns
- Suppliers of instruments, reagents, and analytical tools that read patient genomes and monitor treatment responses, earning revenue across the entire precision medicine workflow. · DanaherSells bioprocessing and diagnostics tools that every genetic medicine maker buys, earning revenue from sector growth rather than individual drug success., Thermo Fisher ScientificSupplies instruments, reagents, and contract manufacturing across genetic medicine programs, collecting revenue regardless of which specific therapy succeeds., IlluminaSequencers read tumor genomes used to design custom vaccines, making the platform a critical step in the personalization workflow., Agilent TechnologiesSupplies analytical and quality-control instruments used daily across drug development and diagnostics, earning revenue from sector growth without backing any single winner., Twist BioscienceManufactures synthetic DNA used by vaccine designers, gene editors, and sequencing panels, serving as a foundational input across personalized medicine., 10x GenomicsSingle-cell and spatial analysis tools help researchers understand tumors and immune responses, providing the scientific foundation for personalized therapy design.26%
- Established pharmaceutical companies partnered with or committed to personalized medicine platforms, providing capital and commercial reach to validate the sector's growth. · Merck & CoPartnered with Moderna on a personalized cancer vaccine paired with its oncology franchise, sharing upside from mRNA platform success without sole dependence on the program., AstraZenecaAdvanced deeper than most large pharmaceutical companies into targeted cancer drugs matched to tumor genetics, providing exposure to precision medicine adoption., NovartisAlready commercializes gene therapies and RNA-based drugs, demonstrating that large pharmaceutical companies can profitably scale genetic medicine., SanofiCommitted billions to mRNA vaccines and immunology after acquiring Translate Bio, making it the large pharmaceutical company most explicitly betting on platform expansion beyond Covid.22%
- Companies developing the core technologies, mRNA, RNA interference, gene editing, and self-amplifying therapeutics, that enable customized treatments across multiple disease areas. · ModernaDevelops individualized cancer vaccines in late-stage trials, representing the purest bet that mRNA becomes a broad therapeutic platform beyond infectious disease., BioNTechBuilt its foundation on individualized cancer immunotherapy and holds a broad oncology pipeline with substantial cash to fund advancement through clinical trials., Alnylam PharmaceuticalsMultiple approved RNA-silencing drugs demonstrate that programmable genetic medicine is a viable commercial business, validating the platform concept., CRISPR TherapeuticsFirst CRISPR medicine approved and pipeline targeting cancer and heart disease, representing the highest-risk platform bet with the most upside if therapies advance., Arcturus TherapeuticsSelf-amplifying mRNA technology works at lower doses with an approved Covid vaccine in Japan and partnered programs advancing through trials.20%
- Suppliers of components, materials, and equipment used to manufacture and deliver genetic medicines at scale, benefiting from growth in approved therapies and manufacturing capacity. · West Pharmaceutical ServicesMakes stoppers, seals, and delivery components for injectable biologics including mRNA vaccines, earning more with each approved genetic medicine., RepligenSells filtration and purification equipment for biologics and mRNA manufacturing, providing consumables bought repeatedly as production scales., AvantorDistributes chemicals, single-use kits, and supplies for biopharmaceutical production, with revenue tracking sector activity rather than individual programs., Maravai LifeSciencesProduces CleanCap and critical inputs for mRNA manufacturing, offering direct exposure to mRNA becoming a standard drug class.13%
- Diagnostic platforms that identify which patients need personalized treatment and track whether therapies work, acting as gatekeepers for therapy selection and adoption. · NateraSignatera detects tumor DNA in blood, identifying candidates for personalized vaccines and measuring whether treatments work as intended., Guardant HealthBlood-based cancer profiling opens the door to personalized treatment by identifying tumors before therapy selection., Tempus AIConverts genomic and clinical data into treatment recommendations and trial matching, providing the software layer personalized medicine needs to scale.11%
- Cash8%